87 related articles for article (PubMed ID: 27150534)
1. Uveal Melanomas Harbor Recurrent Activating Mutations in CYSLTR2.
Cancer Discov; 2016 Jun; 6(6):573. PubMed ID: 27150534
[TBL] [Abstract][Full Text] [Related]
2. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
Moore AR; Ceraudo E; Sher JJ; Guan Y; Shoushtari AN; Chang MT; Zhang JQ; Walczak EG; Kazmi MA; Taylor BS; Huber T; Chi P; Sakmar TP; Chen Y
Nat Genet; 2016 Jun; 48(6):675-80. PubMed ID: 27089179
[TBL] [Abstract][Full Text] [Related]
3. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.
Ceraudo E; Horioka M; Mattheisen JM; Hitchman TD; Moore AR; Kazmi MA; Chi P; Chen Y; Sakmar TP; Huber T
J Biol Chem; 2021; 296():100163. PubMed ID: 33288675
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.
Slater K; Hoo PS; Buckley AM; Piulats JM; Villanueva A; Portela A; Kennedy BN
Cancer Metastasis Rev; 2018 Sep; 37(2-3):335-345. PubMed ID: 30094568
[TBL] [Abstract][Full Text] [Related]
5. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.
Nell RJ; Menger NV; Versluis M; Luyten GPM; Verdijk RM; Madigan MC; Jager MJ; van der Velden PA
BMC Cancer; 2021 Feb; 21(1):164. PubMed ID: 33588787
[TBL] [Abstract][Full Text] [Related]
6. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
7. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
8. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
[TBL] [Abstract][Full Text] [Related]
9. Whole-exome sequencing of a meningeal melanocytic tumour reveals activating CYSLTR2 and EIF1AX hotspot mutations and similarities to uveal melanoma.
Küsters-Vandevelde HVN; Germans MR; Rabbie R; Rashid M; Ten Broek R; Blokx WAM; Prinsen CFM; Adams DJ; Ter Laan M
Brain Tumor Pathol; 2018 Apr; 35(2):127-130. PubMed ID: 29476293
[No Abstract] [Full Text] [Related]
10. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
11. Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.
van de Nes JAP; Koelsche C; Gessi M; Möller I; Sucker A; Scolyer RA; Buckland ME; Pietsch T; Murali R; Schadendorf D; Griewank KG
J Invest Dermatol; 2017 Sep; 137(9):2033-2035. PubMed ID: 28499758
[No Abstract] [Full Text] [Related]
12. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.
Brantley MA; Harbour JW
Cancer Res; 2000 Aug; 60(16):4320-3. PubMed ID: 10969768
[TBL] [Abstract][Full Text] [Related]
13. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas.
Pópulo H; Vinagre J; Lopes JM; Soares P
Br J Ophthalmol; 2011 May; 95(5):715-9. PubMed ID: 20805136
[TBL] [Abstract][Full Text] [Related]
14. Status of the NF1 tumor suppressor locus in uveal melanoma.
Foster WJ; Fuller CE; Perry A; Harbour JW
Arch Ophthalmol; 2003 Sep; 121(9):1311-5. PubMed ID: 12963615
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of chemokine receptors on uveal melanoma cells and their metastases.
Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):636-43. PubMed ID: 18235009
[TBL] [Abstract][Full Text] [Related]
16. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
17. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
18. Infrequent expression of the MAGE gene family in uveal melanomas.
Mulcahy KA; Rimoldi D; Brasseur F; Rodgers S; Liénard D; Marchand M; Rennie IG; Murray AK; McIntyre CA; Platts KE; Leyvraz S; Boon T; Rees RC
Int J Cancer; 1996 Jun; 66(6):738-42. PubMed ID: 8647642
[TBL] [Abstract][Full Text] [Related]
19. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
Maat W; Beiboer SH; Jager MJ; Luyten GP; Gruis NA; van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1291-8. PubMed ID: 18385040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
